Decipher Biosciences Inc. (Decipher) is a genomic classifier (GC) that could help estimate the risk of distant metastasis (DM) after radical prostatectomy in patients with prostate cancer. The effectiveness of the classifier is not known. This study aims to validate the Decipher GC for patients with recurring prostate cancer.
This ancillary study included samples of a total of 352 patients with recurrent prostate cancer. The specimens of samples with the highest-grade tumor available at the time of the study were extracted. The included participants were assigned to receive salvage radiotherapy (sRT) with or without 2 years of bicalutamide. The primary outcome of the study was the independent association of GC with eh development of DM.
Multivariable analysis of the eligible samples showed that GC was independently associated with DM, prostate-cancer-specific mortality (PCSM), and overall survival (OS). GC was not associated with age, T stage, margin status, entry prostate-specific antigen, Gleason score, and treatment arm. The findings also suggested that the absolute effect of bicalutamide on 12-year OS was less when comparing patients with low vs. high GC scores.
The research concluded that Decipher GC was independently associated with DM, PCSM, and OS in patients with recurrent prostate cancer.
Ref: https://jamanetwork.com/journals/jamaoncology/article-abstract/2776225?resultClick=1
